Učitavanje...
HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant
BACKGROUND: Subsets of high grade endometrial cancer (EnCa) over-express HER2 (ERBB2), yet clinical trials have failed to demonstrate any anti-tumor activity utilizing trastuzumab, an approved platform for HER2 positive breast cancer (BrCa). A truncated p95HER2 variant lacking the trastuzumab bindin...
Spremljeno u:
| Izdano u: | Gynecol Oncol |
|---|---|
| Glavni autori: | , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4380649/ https://ncbi.nlm.nih.gov/pubmed/25602714 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.01.533 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|